These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 32198977)

  • 21. Melanocyte-keratinocyte cross-talk in vitiligo.
    Touni AA; Shivde RS; Echuri H; Abdel-Aziz RTA; Abdel-Wahab H; Kundu RV; Le Poole IC
    Front Med (Lausanne); 2023; 10():1176781. PubMed ID: 37275386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vitiligo.
    Picardo M; Dell'Anna ML; Ezzedine K; Hamzavi I; Harris JE; Parsad D; Taieb A
    Nat Rev Dis Primers; 2015 Jun; 1():15011. PubMed ID: 27189851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8.
    Toosi S; Orlow SJ; Manga P
    J Invest Dermatol; 2012 Nov; 132(11):2601-9. PubMed ID: 22696056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Concise Review on the Role of Endoplasmic Reticulum Stress in the Development of Autoimmunity in Vitiligo Pathogenesis.
    Jadeja SD; Mayatra JM; Vaishnav J; Shukla N; Begum R
    Front Immunol; 2020; 11():624566. PubMed ID: 33613564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New insights into immune mechanisms of vitiligo.
    Boniface K; Taïeb A; Seneschal J
    G Ital Dermatol Venereol; 2016 Feb; 151(1):44-54. PubMed ID: 26512930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment update for vitiligo based on autoimmune inhibition and melanocyte protection.
    Xie B; Zhu Y; Shen Y; Xu W; Song X
    Expert Opin Ther Targets; 2023 Mar; 27(3):189-206. PubMed ID: 36947026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitiligo: where do we stand?
    Ortonne JP; Bose SK
    Pigment Cell Res; 1993 Mar; 6(2):61-72. PubMed ID: 8321867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. On the etiology of contact/occupational vitiligo.
    Boissy RE; Manga P
    Pigment Cell Res; 2004 Jun; 17(3):208-14. PubMed ID: 15140065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melanocyte destruction and repopulation in vitiligo.
    Norris DA; Horikawa T; Morelli JG
    Pigment Cell Res; 1994 Aug; 7(4):193-203. PubMed ID: 7855062
    [No Abstract]   [Full Text] [Related]  

  • 30. Mutant HSP70 reverses autoimmune depigmentation in vitiligo.
    Mosenson JA; Zloza A; Nieland JD; Garrett-Mayer E; Eby JM; Huelsmann EJ; Kumar P; Denman CJ; Lacek AT; Kohlhapp FJ; Alamiri A; Hughes T; Bines SD; Kaufman HL; Overbeck A; Mehrotra S; Hernandez C; Nishimura MI; Guevara-Patino JA; Le Poole IC
    Sci Transl Med; 2013 Feb; 5(174):174ra28. PubMed ID: 23447019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo.
    Wang Y; Li S; Li C
    Clin Rev Allergy Immunol; 2021 Dec; 61(3):299-323. PubMed ID: 34283349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of oxidative stress and autoimmunity in onset and progression of vitiligo.
    Laddha NC; Dwivedi M; Mansuri MS; Singh M; Gani AR; Yeola AP; Panchal VN; Khan F; Dave DJ; Patel A; Madhavan SE; Gupta R; Marfatia Z; Marfatia YS; Begum R
    Exp Dermatol; 2014 May; 23(5):352-3. PubMed ID: 24628992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The possible role of Wnt/β-catenin signalling in vitiligo treatment.
    Lin X; Meng X; Lin J
    J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2208-2221. PubMed ID: 36912722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-17 induces cellular stress microenvironment of melanocytes to promote autophagic cell apoptosis in vitiligo.
    Zhou J; An X; Dong J; Wang Y; Zhong H; Duan L; Ling J; Ping F; Shang J
    FASEB J; 2018 Sep; 32(9):4899-4916. PubMed ID: 29613836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoimmunity as an aetiological factor in vitiligo.
    Rezaei N; Gavalas NG; Weetman AP; Kemp EH
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):865-76. PubMed ID: 17658994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitiligo and Hashimoto's thyroiditis: Autoimmune diseases linked by clinical presentation, biochemical commonality, and autoimmune/oxidative stress-mediated toxicity pathogenesis.
    Li D; Liang G; Calderone R; Bellanti JA
    Med Hypotheses; 2019 Jul; 128():69-75. PubMed ID: 31203913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melanocyte Regeneration in Vitiligo Requires WNT beneath their Wings.
    Harris JE
    J Invest Dermatol; 2015 Dec; 135(12):2921-2923. PubMed ID: 26569586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repigmentation through Melanocyte Regeneration in Vitiligo.
    Birlea SA; Goldstein NB; Norris DA
    Dermatol Clin; 2017 Apr; 35(2):205-218. PubMed ID: 28317529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic management of vitiligo.
    Bleuel R; Eberlein B
    J Dtsch Dermatol Ges; 2018 Nov; 16(11):1309-1313. PubMed ID: 30335222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Ultraviolet Light on Vitiligo.
    Singh RK
    Adv Exp Med Biol; 2017; 996():55-60. PubMed ID: 29124690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.